Literature DB >> 28362428

Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells.

Izumi Horikawa1, Kye-Yoon Park2, Kazunobu Isogaya1, Yukiharu Hiyoshi1, Han Li3, Katsuhiro Anami1, Ana I Robles1, Abdul M Mondal1, Kaori Fujita1, Manuel Serrano3, Curtis C Harris1.   

Abstract

p53 functions to induce cellular senescence, which is incompatible with self-renewal of pluripotent stem cells such as induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC). However, p53 also has essential roles in these cells through DNA damage repair for maintaining genomic integrity and high sensitivity to apoptosis for eliminating severely damaged cells. We hypothesized that Δ133p53, a physiological inhibitory p53 isoform, is involved in the balanced regulation of self-renewing capacity, DNA damage repair and apoptosis. We examined 12 lines of human iPSC and their original fibroblasts, as well as three ESC lines, for endogenous protein levels of Δ133p53 and full-length p53 (FL-p53), and mRNA levels of various p53 target genes. While FL-p53 levels in iPSC and ESC widely ranged from below to above those in the fibroblasts, all iPSC and ESC lines expressed elevated levels of Δ133p53. The p53-inducible genes that mediate cellular senescence (p21WAF1, miR-34a, PAI-1 and IGFBP7), but not those for apoptosis (BAX and PUMA) and DNA damage repair (p53R2), were downregulated in iPSC and ESC. Consistent with these endogenous expression profiles, overexpression of Δ133p53 in human fibroblasts preferentially repressed the p53-inducible senescence mediators and significantly enhanced their reprogramming to iPSC. The iPSC lines derived from Δ133p53-overexpressing fibroblasts formed well-differentiated, benign teratomas in immunodeficient mice and had fewer numbers of somatic mutations than an iPSC derived from p53-knocked-down fibroblasts, suggesting that Δ133p53 overexpression is non- or less oncogenic and mutagenic than total inhibition of p53 activities. Overexpressed Δ133p53 prevented FL-p53 from binding to the regulatory regions of p21WAF1 and miR-34a promoters, providing a mechanistic basis for its dominant-negative inhibition of a subset of p53 target genes. This study supports the hypothesis that upregulation of Δ133p53 is an endogenous mechanism that facilitates human somatic cells to become self-renewing pluripotent stem cells with maintained apoptotic and DNA repair activities.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28362428      PMCID: PMC5442472          DOI: 10.1038/cdd.2017.48

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  58 in total

Review 1.  Ubiquitination and selective autophagy.

Authors:  S Shaid; C H Brandts; H Serve; I Dikic
Journal:  Cell Death Differ       Date:  2012-06-22       Impact factor: 15.828

Review 2.  p53: guardian of reprogramming.

Authors:  Sergio Menendez; Suzanne Camus; Juan Carlos Izpisua Belmonte
Journal:  Cell Cycle       Date:  2010-10-09       Impact factor: 4.534

Review 3.  p53 and stem cells: new developments and new concerns.

Authors:  Tongbiao Zhao; Yang Xu
Journal:  Trends Cell Biol       Date:  2010-01-12       Impact factor: 20.808

4.  The Regulation of Aging and Longevity: A New and Complex Role of p53.

Authors:  Zhaohui Feng; Meihua Lin; Rui Wu
Journal:  Genes Cancer       Date:  2011-04

5.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

6.  Sequence variations of mitochondrial DNA D-loop region are highly frequent events in familial breast cancer.

Authors:  Man Yu; Yurong Shi; Fei Zhang; Yunli Zhou; Yi Yang; Xiyin Wei; Lin Zhang; Ruifang Niu
Journal:  J Biomed Sci       Date:  2007-12-22       Impact factor: 8.410

7.  Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.

Authors:  Alice Bourdon; Limor Minai; Valérie Serre; Jean-Philippe Jais; Emmanuelle Sarzi; Sophie Aubert; Dominique Chrétien; Pascale de Lonlay; Véronique Paquis-Flucklinger; Hirofumi Arakawa; Yusuke Nakamura; Arnold Munnich; Agnès Rötig
Journal:  Nat Genet       Date:  2007-05-07       Impact factor: 38.330

8.  Stem cells: The promises and perils of p53.

Authors:  Valery Krizhanovsky; Scott W Lowe
Journal:  Nature       Date:  2009-08-27       Impact factor: 49.962

9.  Senescence impairs successful reprogramming to pluripotent stem cells.

Authors:  Ana Banito; Sheikh T Rashid; Juan Carlos Acosta; SiDe Li; Carlos F Pereira; Imbisaat Geti; Sandra Pinho; Jose C Silva; Veronique Azuara; Martin Walsh; Ludovic Vallier; Jesús Gil
Journal:  Genes Dev       Date:  2009-08-20       Impact factor: 11.361

10.  Somatic coding mutations in human induced pluripotent stem cells.

Authors:  Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

View more
  25 in total

1.  Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats.

Authors:  Jay S Mishra; Amar S More; Sathish Kumar
Journal:  Biol Reprod       Date:  2018-04-01       Impact factor: 4.285

2.  Δ133p53: A p53 isoform enriched in human pluripotent stem cells.

Authors:  Izumi Horikawa; Curtis C Harris
Journal:  Cell Cycle       Date:  2017-07-20       Impact factor: 4.534

3.  Radiation-induced astrocyte senescence is rescued by Δ133p53.

Authors:  Casmir Turnquist; Jessica A Beck; Izumi Horikawa; Ifeyinwa E Obiorah; Natalia Von Muhlinen; Borivoj Vojtesek; David P Lane; Christopher Grunseich; Joeffrey J Chahine; Heather M Ames; Dee Dee Smart; Brent T Harris; Curtis C Harris
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

4.  Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms.

Authors:  Jessica Beck; Casmir Turnquist; Izumi Horikawa; Curtis Harris
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 5.  TGF-β1/p53 signaling in renal fibrogenesis.

Authors:  Stephen P Higgins; Yi Tang; Craig E Higgins; Badar Mian; Wenzheng Zhang; Ralf-Peter Czekay; Rohan Samarakoon; David J Conti; Paul J Higgins
Journal:  Cell Signal       Date:  2017-11-28       Impact factor: 4.315

Review 6.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

7.  Astrocyte senescence and SASP in neurodegeneration: tau joins the loop.

Authors:  Kyra Ungerleider; Jessica Beck; Delphine Lissa; Casmir Turnquist; Izumi Horikawa; Brent T Harris; Curtis C Harris
Journal:  Cell Cycle       Date:  2021-04-05       Impact factor: 4.534

8.  A functional interplay between Δ133p53 and ΔNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation.

Authors:  Lu Gong; Xiao Pan; Chuan-Bian Lim; Anna de Polo; John B Little; Zhi-Min Yuan
Journal:  Oncogene       Date:  2018-01-26       Impact factor: 9.867

9.  ΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer.

Authors:  Javier Rodríguez-Cobos; David Viñal; Carmen Poves; María J Fernández-Aceñero; Héctor Peinado; Daniel Pastor-Morate; Mª Isabel Prieto; Rodrigo Barderas; Nuria Rodríguez-Salas; Gemma Domínguez
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

10.  Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.

Authors:  Kevin Jan Legscha; Edite Antunes Ferreira; Antonios Chamoun; Alexander Lang; Mohamed Hemaid Sayed Awwad; Gigi Nu Hoang Quy Ton; Danuta Galetzka; Borhane Guezguez; Michael Hundemer; Jean-Christophe Bourdon; Markus Munder; Matthias Theobald; Hakim Echchannaoui
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.